A Study to Compare Ocular Safety and Tolerability of Prednisolone Acetate 0.5% Eye Drops Versus Vehicle in Healthy Volunteers

Novartis

Status and phase

Completed

Phase 4

Conditions

Healthy

Treatments

Drug: Prednisolone acetate

Study type

Interventional

Funder types

Industry

Identifiers

NCT00134992

CULT 491 DE 02

Details and patient eligibility

About

The objective of this trial was to confirm the tolerability of prednisolone acetate 0.5% eye drops by testing the hypothesis that the ocular safety and tolerability of prednisolone acetate 0.5% eye drops are equivalent to vehicle. Thus healthy volunteers have been selected and have been treated by using a crossover design.

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy subjects of either gender, 18 years or older, who were able to give an informed consent
A score for ocular discomfort of 0-20 mm on the visual analogue scale (VAS) prior to treatment

Exclusion criteria

Known hypersensitivity to any of the constituents of the medications
Known corticosteroid responder (elevation of intraocular pressure [IOP])
Known allergic disposition (e.g. hay fever)
Need of ocular antiallergic treatment
Wearing of contact lenses
Any kind of current eye disease (e.g. dry eye)
Any kind of concomitant ocular treatment
Any injury or infection in either eye during the last 3 months prior to the first application
Any medication taken within the last 28 days prior to the first application, except hormonal contraceptives
Concomitant or previous treatment with antihistamines within a week prior to enrolment
Pregnant or breast feeding women
Participation in another clinical study within 4 weeks prior to enrolment
Hematological diseases such as aplastic anemia, panmyelopathy, or hemolytic icterus; with severe dysfunction of the liver.
Any medical or laboratory condition which, in the Investigator's opinion, would preclude the participant from adhering to the protocol or completing the trial per protocol
Subjects with history of malignancy of any organ system, treated or untreated, within the past five years, whether or not evidence of local recurrence or metastases exist, are excluded, with the exception of localized basal cell carcinoma of the skin